Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 3.7%

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) fell 3.7% during trading on Thursday . The stock traded as low as $21.12 and last traded at $21.13. 96,197 shares traded hands during mid-day trading, a decline of 91% from the average session volume of 1,095,406 shares. The stock had previously closed at $21.94.

Analyst Ratings Changes

A number of analysts have weighed in on the company. HC Wainwright reiterated a "buy" rating and issued a $41.00 price target on shares of Syndax Pharmaceuticals in a research report on Thursday, May 9th. Citigroup lowered their target price on shares of Syndax Pharmaceuticals from $32.00 to $30.00 and set a "buy" rating on the stock in a report on Thursday, May 9th. JPMorgan Chase & Co. lifted their price target on shares of Syndax Pharmaceuticals from $31.00 to $34.00 and gave the company an "overweight" rating in a report on Wednesday, March 20th. Scotiabank cut shares of Syndax Pharmaceuticals from a "sector outperform" rating to a "sector perform" rating and decreased their price objective for the stock from $36.00 to $23.00 in a research note on Wednesday, January 31st. Finally, Stifel Nicolaus raised their price objective on shares of Syndax Pharmaceuticals from $39.00 to $40.00 and gave the stock a "buy" rating in a report on Thursday, May 9th. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company's stock. According to MarketBeat, Syndax Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $34.42.

Syndax Pharmaceuticals Stock Performance

The firm's 50-day moving average is $22.29 and its two-hundred day moving average is $20.50. The stock has a market cap of $1.78 billion, a P/E ratio of -6.50 and a beta of 1.01.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its earnings results on Wednesday, May 8th. The company reported ($0.85) earnings per share for the quarter, topping analysts' consensus estimates of ($0.96) by $0.11. During the same period in the prior year, the company posted ($0.59) EPS. As a group, research analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.58 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC bought a new stake in shares of Syndax Pharmaceuticals during the third quarter worth approximately $143,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Syndax Pharmaceuticals by 6.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 42,192 shares of the company's stock valued at $613,000 after purchasing an additional 2,700 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in shares of Syndax Pharmaceuticals by 97.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,782 shares of the company's stock worth $26,000 after purchasing an additional 880 shares during the last quarter. Teacher Retirement System of Texas grew its stake in shares of Syndax Pharmaceuticals by 5.1% during the third quarter. Teacher Retirement System of Texas now owns 15,619 shares of the company's stock worth $227,000 after purchasing an additional 757 shares during the period. Finally, Principal Financial Group Inc. increased its holdings in Syndax Pharmaceuticals by 27.8% in the third quarter. Principal Financial Group Inc. now owns 43,120 shares of the company's stock valued at $626,000 after purchasing an additional 9,371 shares during the last quarter.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).